Kendle International — UBS Global Life Sciences Conference 2008
35 slides from Kendle International's conference presentation, Sep 24, 2008
Slide 1: UBS Global Life Sciences Conference
UBS Global Life Sciences Conference New York City September 24, 2008 Exhibit 99.1
Slide 2: Safe Harbor
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Safe Harbor • Information herein contains forward - looking statements pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All such forward- looking stat
Slide 3: CRO market opportunity accelerating within a decelerating pharma market
9.3% Global CRO market growth and global R&D spending exceeding overall pharma market growth 13-15% N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Source: Goldman Sachs, May 20, 2008. Global R&D spending Overall pharma market 6.6% Global CRO m
Slide 4: Our vision: Customer and business expansion
Customer and business expansion to accelerate growth Operational continuity and leverage via the matrix Infrastructure growth to drive global connectivity Kendle Our vision
Slide 5: Our vision: best-in-class provider of clinical development services
“Best-in-class” provider of clinical development services to the biopharmaceutical industry through broad therapeutic and geographic expertise N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Our vision
Slide 6: Our vision: Operational continuity and leverage via the matrix
Kendle Operational continuity and leverage via the matrix Our vision
Slide 7: Best in Class Provider
Best in Class Provider Therapeutic Expertise Geographic Expertise Kendle High quality driven by Kendle’s 5 Brands Excellence driven by leveraging the matrix of 5 Brands across 5 geographic regions Experience driven by leveraging the matrix of 5 Brands across 5 geographic regions
Slide 8: Our vision: Customer and business expansion to accelerate growth
Customer and business expansion to accelerate growth Kendle Our vision
Slide 9: Customer Development
Customer Development Strategic Relationships Full Service Megatrials Execution across global footprint * High customer need: R&D efficiency and Delivery Confidence * High shareholder value: Repeat business and Efficiencies + Growth opportunities « Supports Expansion + Leverage Best-in-class geograph
Slide 10: Customer drivers for R&D efficiency
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Source: Jefferies, CRO Survey, March 2007 % of total respondents Vendor relationship management principles Electronic data capture (EDC) Functional outsourcing Preferred provider agreements Centra
Slide 11: Full service megatrials: the need for global capability
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a • Geographic reach over five regions • Strong project leadership for large global trials • Workforce needs • Efficiency and productivity through technology Full service megatrials The need for glo
Slide 12: Execution across global footprint: patient access
Kendle Real people Real sus? Execution across global footprint Patient access Expected development spending Allocation of development spending allocation by 2011; significant increase in Asia/Pacific, Other by global region — 2007 Other Asial 9% Other Pacific: 8% Us. 26% EU 23% ; Us. 60% Asial Pacif
Slide 13: Continuing globalization
Continuing globalization Kendle Real people Real results Revenue moves away from United States into global markets with a shift from 50% in Q2 2007 to 45% in Q2 2008 92 2007 5%, Latin America grows from 5% of ° total revenue in Q2 2007 to 8% of total revenue in Q2 2008 92 2007 45% 92 2008 92 2008 13
Slide 14: Slide 14
Slide 15: Slide 15
Slide 16: Slide 16
Slide 17: Slide 17
Slide 18: Slide 18
Slide 19: Slide 19
Slide 20: Early Stage Opportunities; Geographic Expansion; Business expansion
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Early Stage Opportunities Geographic Expansion Customer and business expansion Business expansion
Slide 21: Preclinical/Phase I opportunity
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Preclinical/Phase I opportunity Source: Goldman Sachs, Pharmaceutical Services, Dec 2007 and May 2008 Phase I Compounds in Development by Year, Month Preclinical/Phase I a $9.8 billion market by 2
Slide 22: Shift in opportunity by phase
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Shift in opportunity by phase Source: William Blair & Company, CRO Industry Update , Oct. 5, 2007. New compounds in pharmaceutical development, 1995 to present
Slide 23: Early Stage
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Early Stage • Phase I growth is expected to outpace broader market at approximately 15-16% annually • Early Stage will grow to approximately 20% of our business over the next 3 years Utrecht Toron
Slide 24: Asia/Pacific
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Asia/Pacific • Asia/Pacific growth is estimated at 30-50% through 2013 • Kendle’s focus is expanded breadth and depth of key markets to win and deliver megatrials Current Kendle operations Markets
Slide 25: Our vision: Infrastructure growth to drive global connectivity
Kendle Our vision Infrastructure growth to drive global connectivity
Slide 26: Infrastructure growth to drive global connectivity
Kendle Real people Real sults? Infrastructure growth to drive global connectivity Functional Finance, Business orientation Commercial Operations and sophistication Operational ee Bie uncae Leadership Leverage Global connectivity System/Processes Infrastructure/ERP. Beet ae
Slide 27: Financial Profile
Financial Profile
Slide 28: Delivering value for shareholders
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Delivering value for shareholders
Slide 29: Strong Growth in Net Sales
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Strong Growth in Net Sales
Slide 30: Strong Growth in Backlog
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Strong Growth in Backlog
Slide 31: Growth in Revenues
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Growth in Revenues * Peer Group includes PPD, Parexel, PRA and ICON for 2004-2006. 2007 and 2008 excludes PRA. **Includes acquisition of Charles River Laboratories Clinical Services (CRLCS) as of
Slide 32: Operating Margin Comparison
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Operating Margin Comparison *Peer Group includes PPD, Parexel, PRA and ICON for 2004-2006. 2007 and 2008 exclude PRA. ** Proforma operating margin for full year 2006 excludes charges for stock opt
Slide 33: 2008 Guidance
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a 2008 Guidance * Amounts in Millions
Slide 34: Summary for Q3
Kendle Real people Real sults? Summary for Q3 + At the current Street consensus; Consensus is $126.9M + At or above current Street consensus; Consensus is $0.56
Slide 35: r i c a
N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a
Kendle International — UBS Global Life Sciences Conference 2008 on 6ix